Does the media refer more to PALI or XERS?

In the previous week, Xeris Biopharma had 2 more articles in the media than Palisade Bio. MarketBeat recorded 7 mentions for Xeris Biopharma and 5 mentions for Palisade Bio. Palisade Bio's average media sentiment score of 0.64 beat Xeris Biopharma's score of 0.26 indicating that Palisade Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Palisade Bio 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xeris Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to PALI or COLL?

In the previous week, Palisade Bio had 3 more articles in the media than Collegium Pharmaceutical. MarketBeat recorded 5 mentions for Palisade Bio and 2 mentions for Collegium Pharmaceutical. Collegium Pharmaceutical's average media sentiment score of 0.93 beat Palisade Bio's score of 0.64 indicating that Collegium Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Palisade Bio 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Collegium Pharmaceutical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to PALI or WVE?

In the previous week, WAVE Life Sciences had 1 more articles in the media than Palisade Bio. MarketBeat recorded 6 mentions for WAVE Life Sciences and 5 mentions for Palisade Bio. WAVE Life Sciences' average media sentiment score of 0.88 beat Palisade Bio's score of 0.64 indicating that WAVE Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Palisade Bio 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive WAVE Life Sciences 1 Very Positive mention(s) 4 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to SDGR or PALI?

In the previous week, Palisade Bio had 3 more articles in the media than Schrodinger. MarketBeat recorded 5 mentions for Palisade Bio and 2 mentions for Schrodinger. Schrodinger's average media sentiment score of 0.93 beat Palisade Bio's score of 0.64 indicating that Schrodinger is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Schrodinger 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Palisade Bio 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, CVAC or PALI?

CureVac has higher revenue and earnings than Palisade Bio. Palisade Bio is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CureVac $70.74M 14.78 $175.50M $0.72 6.47 Palisade Bio $250K 1,176.87 -$16.78M -$1.01 N/A

Is CVAC or PALI more profitable?

CureVac has a net margin of 199.92% compared to Palisade Bio's net margin of 0.00%. CureVac's return on equity of -23.03% beat Palisade Bio's return on equity. Company Net Margins Return on Equity Return on Assets CureVac 199.92% -23.03% -19.09% Palisade Bio N/A -36.79% -34.34%

Palisade Bio (PALI) Competitors

$1.70 -0.02 (-0.88%)

As of 12:17 PM Eastern

Compare

PALI vs. XERS, COLL, WVE, SDGR, and CVAC

Should you buy Palisade Bio stock or one of its competitors? MarketBeat compares Palisade Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Palisade Bio include Xeris Biopharma (XERS), Collegium Pharmaceutical (COLL), WAVE Life Sciences (WVE), Schrodinger (SDGR), and CureVac (CVAC). These companies are all part of the "pharmaceutical products" industry.

How does Palisade Bio compare to Xeris Biopharma?

Palisade Bio (NASDAQ:PALI) and Xeris Biopharma (NASDAQ:XERS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, media sentiment, institutional ownership, earnings, valuation and profitability.

Xeris Biopharma has higher revenue and earnings than Palisade Bio. Palisade Bio is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palisade Bio	$250K	1,176.87	-$16.78M	-$1.01	N/A
Xeris Biopharma	$291.85M	4.02	$550K	$0.06	113.25

Palisade Bio presently has a consensus target price of $10.20, suggesting a potential upside of 501.77%. Xeris Biopharma has a consensus target price of $10.80, suggesting a potential upside of 58.94%. Given Palisade Bio's stronger consensus rating and higher probable upside, equities research analysts clearly believe Palisade Bio is more favorable than Xeris Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

In the previous week, Xeris Biopharma had 2 more articles in the media than Palisade Bio. MarketBeat recorded 7 mentions for Xeris Biopharma and 5 mentions for Palisade Bio. Palisade Bio's average media sentiment score of 0.64 beat Xeris Biopharma's score of 0.26 indicating that Palisade Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Palisade Bio	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xeris Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Palisade Bio has a beta of 1.52, meaning that its stock price is 52% more volatile than the broader market. Comparatively, Xeris Biopharma has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market.

11.8% of Palisade Bio shares are held by institutional investors. Comparatively, 42.8% of Xeris Biopharma shares are held by institutional investors. 0.1% of Palisade Bio shares are held by insiders. Comparatively, 4.4% of Xeris Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Xeris Biopharma has a net margin of 3.81% compared to Palisade Bio's net margin of 0.00%. Xeris Biopharma's return on equity of 735.00% beat Palisade Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Palisade Bio	N/A	-36.79%	-34.34%
Xeris Biopharma	3.81%	735.00%	3.24%

Summary

Xeris Biopharma beats Palisade Bio on 10 of the 17 factors compared between the two stocks.

How does Palisade Bio compare to Collegium Pharmaceutical?

Palisade Bio (NASDAQ:PALI) and Collegium Pharmaceutical (NASDAQ:COLL) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, dividends, valuation and earnings.

Palisade Bio currently has a consensus price target of $10.20, indicating a potential upside of 501.77%. Collegium Pharmaceutical has a consensus price target of $57.50, indicating a potential upside of 67.47%. Given Palisade Bio's stronger consensus rating and higher possible upside, research analysts plainly believe Palisade Bio is more favorable than Collegium Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Collegium Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67

Collegium Pharmaceutical has a net margin of 9.41% compared to Palisade Bio's net margin of 0.00%. Collegium Pharmaceutical's return on equity of 95.18% beat Palisade Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Palisade Bio	N/A	-36.79%	-34.34%
Collegium Pharmaceutical	9.41%	95.18%	16.39%

Collegium Pharmaceutical has higher revenue and earnings than Palisade Bio. Palisade Bio is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palisade Bio	$250K	1,176.87	-$16.78M	-$1.01	N/A
Collegium Pharmaceutical	$780.57M	1.43	$62.87M	$2.04	16.83

In the previous week, Palisade Bio had 3 more articles in the media than Collegium Pharmaceutical. MarketBeat recorded 5 mentions for Palisade Bio and 2 mentions for Collegium Pharmaceutical. Collegium Pharmaceutical's average media sentiment score of 0.93 beat Palisade Bio's score of 0.64 indicating that Collegium Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Palisade Bio	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Collegium Pharmaceutical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Palisade Bio has a beta of 1.52, indicating that its stock price is 52% more volatile than the broader market. Comparatively, Collegium Pharmaceutical has a beta of 0.75, indicating that its stock price is 25% less volatile than the broader market.

11.8% of Palisade Bio shares are held by institutional investors. 0.1% of Palisade Bio shares are held by company insiders. Comparatively, 1.9% of Collegium Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Collegium Pharmaceutical beats Palisade Bio on 9 of the 17 factors compared between the two stocks.

How does Palisade Bio compare to WAVE Life Sciences?

Palisade Bio (NASDAQ:PALI) and WAVE Life Sciences (NASDAQ:WVE) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, institutional ownership, analyst recommendations and risk.

Palisade Bio presently has a consensus target price of $10.20, suggesting a potential upside of 501.77%. WAVE Life Sciences has a consensus target price of $26.41, suggesting a potential upside of 348.04%. Given Palisade Bio's stronger consensus rating and higher probable upside, research analysts clearly believe Palisade Bio is more favorable than WAVE Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
WAVE Life Sciences	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.87

11.8% of Palisade Bio shares are held by institutional investors. Comparatively, 89.7% of WAVE Life Sciences shares are held by institutional investors. 0.1% of Palisade Bio shares are held by insiders. Comparatively, 24.3% of WAVE Life Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Palisade Bio has higher earnings, but lower revenue than WAVE Life Sciences. WAVE Life Sciences is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palisade Bio	$250K	1,176.87	-$16.78M	-$1.01	N/A
WAVE Life Sciences	$42.73M	26.54	-$204.38M	-$1.06	N/A

Palisade Bio has a beta of 1.52, indicating that its share price is 52% more volatile than the broader market. Comparatively, WAVE Life Sciences has a beta of -1.33, indicating that its share price is 233% less volatile than the broader market.

In the previous week, WAVE Life Sciences had 1 more articles in the media than Palisade Bio. MarketBeat recorded 6 mentions for WAVE Life Sciences and 5 mentions for Palisade Bio. WAVE Life Sciences' average media sentiment score of 0.88 beat Palisade Bio's score of 0.64 indicating that WAVE Life Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Palisade Bio	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
WAVE Life Sciences	1 Very Positive mention(s)	4 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Palisade Bio has a net margin of 0.00% compared to WAVE Life Sciences' net margin of -255.70%. Palisade Bio's return on equity of -36.79% beat WAVE Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Palisade Bio	N/A	-36.79%	-34.34%
WAVE Life Sciences	-255.70%	-56.76%	-42.80%

Summary

Palisade Bio beats WAVE Life Sciences on 11 of the 17 factors compared between the two stocks.

How does Palisade Bio compare to Schrodinger?

Schrodinger (NASDAQ:SDGR) and Palisade Bio (NASDAQ:PALI) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, profitability, media sentiment, institutional ownership, risk, analyst recommendations, earnings and valuation.

79.1% of Schrodinger shares are held by institutional investors. Comparatively, 11.8% of Palisade Bio shares are held by institutional investors. 10.1% of Schrodinger shares are held by company insiders. Comparatively, 0.1% of Palisade Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Schrodinger presently has a consensus price target of $20.25, indicating a potential upside of 35.53%. Palisade Bio has a consensus price target of $10.20, indicating a potential upside of 501.77%. Given Palisade Bio's stronger consensus rating and higher possible upside, analysts plainly believe Palisade Bio is more favorable than Schrodinger.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Schrodinger	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Schrodinger has a beta of 1.64, meaning that its share price is 64% more volatile than the broader market. Comparatively, Palisade Bio has a beta of 1.52, meaning that its share price is 52% more volatile than the broader market.

In the previous week, Palisade Bio had 3 more articles in the media than Schrodinger. MarketBeat recorded 5 mentions for Palisade Bio and 2 mentions for Schrodinger. Schrodinger's average media sentiment score of 0.93 beat Palisade Bio's score of 0.64 indicating that Schrodinger is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Schrodinger	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Palisade Bio	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Palisade Bio has lower revenue, but higher earnings than Schrodinger. Schrodinger is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Schrodinger	$255.87M	4.31	-$103.26M	-$1.41	N/A
Palisade Bio	$250K	1,176.87	-$16.78M	-$1.01	N/A

Palisade Bio has a net margin of 0.00% compared to Schrodinger's net margin of -40.61%. Schrodinger's return on equity of -30.85% beat Palisade Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Schrodinger	-40.61%	-30.85%	-15.32%
Palisade Bio	N/A	-36.79%	-34.34%

Summary

Palisade Bio beats Schrodinger on 10 of the 17 factors compared between the two stocks.

How does Palisade Bio compare to CureVac?

CureVac (NASDAQ:CVAC) and Palisade Bio (NASDAQ:PALI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, media sentiment, earnings, analyst recommendations and profitability.

CureVac has a beta of 1.77, suggesting that its stock price is 77% more volatile than the broader market. Comparatively, Palisade Bio has a beta of 1.52, suggesting that its stock price is 52% more volatile than the broader market.

17.3% of CureVac shares are held by institutional investors. Comparatively, 11.8% of Palisade Bio shares are held by institutional investors. 2.2% of CureVac shares are held by company insiders. Comparatively, 0.1% of Palisade Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

CureVac has a net margin of 199.92% compared to Palisade Bio's net margin of 0.00%. CureVac's return on equity of -23.03% beat Palisade Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CureVac	199.92%	-23.03%	-19.09%
Palisade Bio	N/A	-36.79%	-34.34%

CureVac has higher revenue and earnings than Palisade Bio. Palisade Bio is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47
Palisade Bio	$250K	1,176.87	-$16.78M	-$1.01	N/A

CureVac presently has a consensus target price of $5.50, suggesting a potential upside of 18.03%. Palisade Bio has a consensus target price of $10.20, suggesting a potential upside of 501.77%. Given Palisade Bio's stronger consensus rating and higher possible upside, analysts clearly believe Palisade Bio is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CureVac	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

In the previous week, Palisade Bio had 5 more articles in the media than CureVac. MarketBeat recorded 5 mentions for Palisade Bio and 0 mentions for CureVac. Palisade Bio's average media sentiment score of 0.64 beat CureVac's score of 0.00 indicating that Palisade Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
CureVac	Neutral
Palisade Bio	Positive

Summary

CureVac beats Palisade Bio on 10 of the 17 factors compared between the two stocks.

Get Palisade Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PALI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PALI vs. The Competition

Export

Metric	Palisade Bio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$294.22M	$3.40B	$6.50B	$12.37B
Dividend Yield	N/A	2.25%	2.67%	5.66%
P/E Ratio	-1.68	20.08	24.01	24.71
Price / Sales	1,176.87	326.19	540.55	165.59
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	1.95	8.11	10.55	6.85
Net Income	-$16.78M	$23.89M	$3.56B	$337.45M
7 Day Performance	-2.59%	3.36%	1.54%	2.70%
1 Month Performance	-7.38%	1.34%	2.48%	4.60%
1 Year Performance	164.80%	46.46%	26.49%	32.81%

Palisade Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PALI Palisade Bio	1.8787 of 5 stars	$1.70 -0.9%	$10.20 +501.8%	+167.1%	$294.22M	$250K	N/A	10
XERS Xeris Biopharma	3.0208 of 5 stars	$6.50 +4.2%	$10.80 +66.2%	+56.1%	$1.12B	$291.85M	108.33	290
COLL Collegium Pharmaceutical	3.1791 of 5 stars	$34.40 +3.4%	$57.50 +67.2%	+18.7%	$1.12B	$780.57M	16.86	210
WVE WAVE Life Sciences	3.1234 of 5 stars	$5.78 +1.4%	$27.25 +371.5%	-15.5%	$1.11B	$42.73M	N/A	240
SDGR Schrodinger	2.7932 of 5 stars	$14.52 +0.8%	$20.25 +39.5%	-32.6%	$1.07B	$255.87M	N/A	790	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PALI) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Palisade Bio (PALI) Competitors

PALI vs. XERS, COLL, WVE, SDGR, and CVAC

How does Palisade Bio compare to Xeris Biopharma?

Summary

How does Palisade Bio compare to Collegium Pharmaceutical?

Summary

How does Palisade Bio compare to WAVE Life Sciences?

Summary

How does Palisade Bio compare to Schrodinger?

Summary

How does Palisade Bio compare to CureVac?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PALI vs. The Competition

Palisade Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Palisade Bio (PALI) Competitors

PALI vs. XERS, COLL, WVE, SDGR, and CVAC

How does Palisade Bio compare to Xeris Biopharma?

Which has preferable earnings and valuation, PALI or XERS?

Do analysts recommend PALI or XERS?

Does the media refer more to PALI or XERS?

Which has more volatility & risk, PALI or XERS?

Do insiders & institutionals hold more shares of PALI or XERS?

Is PALI or XERS more profitable?

Summary

How does Palisade Bio compare to Collegium Pharmaceutical?

Do analysts rate PALI or COLL?

Is PALI or COLL more profitable?

Which has better earnings and valuation, PALI or COLL?

Does the media refer more to PALI or COLL?

Which has more volatility and risk, PALI or COLL?

Do institutionals & insiders have more ownership in PALI or COLL?

Summary

How does Palisade Bio compare to WAVE Life Sciences?

Do analysts recommend PALI or WVE?

Do insiders and institutionals hold more shares of PALI or WVE?

Which has higher valuation and earnings, PALI or WVE?

Which has more risk & volatility, PALI or WVE?

Does the media refer more to PALI or WVE?

Is PALI or WVE more profitable?

Summary

How does Palisade Bio compare to Schrodinger?

Do institutionals and insiders believe in SDGR or PALI?

Do analysts recommend SDGR or PALI?

Which has more volatility & risk, SDGR or PALI?

Does the media refer more to SDGR or PALI?

Which has better earnings & valuation, SDGR or PALI?

Is SDGR or PALI more profitable?

Summary

How does Palisade Bio compare to CureVac?

Which has more risk & volatility, CVAC or PALI?

Do institutionals and insiders have more ownership in CVAC or PALI?

Is CVAC or PALI more profitable?

Which has higher valuation and earnings, CVAC or PALI?

Do analysts prefer CVAC or PALI?

Does the media prefer CVAC or PALI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PALI vs. The Competition

Palisade Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools